Skip to main content
ELUT
NASDAQ Life Sciences

Elutia Closes SimpliDerm Sale, Receives $7.7M Cash to Fund NXT-41x Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.951
Mkt Cap
$42.115M
52W Low
$0.5
52W High
$2.5
52W Position info
90% above low
Off High info
62% below high
Rel. Volume
Market data snapshot near publication time

ELUT sits 90% above its 52-week low of $0.5.

Summary

Elutia closed the sale of its SimpliDerm business for $7.7 million in net cash, strengthening its balance sheet to fund NXT-41x through launch. The divestiture is accounted for as a discontinued operation with a $4.9 million gain.


Key Events · M&A and Partnerships · ELUT

  • SimpliDerm Sale Closed

    Elutia completed the sale of its SimpliDerm business to Cellution Biologics on August 17, 2026, receiving $7.7 million in net cash at closing (gross $8 million less $0.3 million inventory adjustment).

  • Non-Dilutive Capital for NXT-41x

    The $7.7 million in proceeds, combined with previously announced funding, is expected to support operations through the first full year of NXT-41x commercial launch in 2028.

  • Contingent Payments Up to $3M

    Elutia may receive up to $2 million for technology transfer milestones and up to $1 million in quarterly earnouts ($250,000 per quarter for five quarters) over the next 18 months.

  • Lien Release on Assets

    The company amended its Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. to release the lien on the SimpliDerm assets.


Analysis · ELUT · Life Sciences

Elutia completed the sale of its SimpliDerm business to Cellution Biologics, receiving $7.7 million in net cash at closing. The divestiture removes a declining revenue stream but provides non-dilutive capital that extends the company's runway through the NXT-41x commercial launch. The transaction also triggered a lien release on the assets under the Avenue Capital loan, and the pro forma financials show a $4.9 million gain. This is a material step in Elutia's pivot to its drug-eluting biomatrix pipeline, though the company still faces Nasdaq delisting risk and ongoing losses.

At the time of this filing, ELUT was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.1M. The 52-week trading range was $0.50 to $2.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELUT - Latest Insights

ELUT
Aug 14, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.941
Real-time Price: $0.9509 info
Change: +$0.0099 (+1%) info
Market Cap: $42.115M info
ELUT
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.871701
Real-time Price: $0.9509 info
Change: +$0.079199 (+9%) info
Market Cap: $42.115M info
ELUT
Aug 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7914
Real-time Price: $0.9509 info
Change: +$0.1595 (+20%) info
Market Cap: $42.115M info
ELUT
Aug 07, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.850
Real-time Price: $0.9509 info
Change: +$0.1009 (+12%) info
Market Cap: $42.115M info
ELUT
Jul 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9351
Real-time Price: $0.9509 info
Change: +$0.0158 (+2%) info
Market Cap: $42.115M info